OXFORD GLOBAL

2nd Annual Advances in Immuno-Oncology Congress

15 - 16 May 2017, London, UK

Day 1 Stream 1 – Discovery of Immuno-Oncology Therapies

- Key therapeutic strategies in immuno-oncology
  - Checkpoint inhibitors
  - CAR T cell therapies
  - Adoptive cell transfer
  - Cancer vaccines & oncolytic viral therapies
- Updates from molecular oncology (including B cell biology and antibody immunity)
- immuno-oncology therapies
  - Radiation therapy
  - Combination therapies
  - NK Cell based therapeutics
- Targeting the PD-1 pathway and finding alternative therapeutic targets
- Immuno-oncology drug discovery case studies

Day 1 Stream 2 – Pre-clinical Immuno-Oncology

- Translational immuno-oncology
- Preclinical Immuno-Oncology
- Mouse Models to Guide Decisions in the Clinic
- Strategic approaches to address the immune checkpoint blockade
- Strategies to increase translatability of preclinical results
- PDX models and their applications
- Biomarker-based selection in preclinical and clinical trials
- Personalised immunotherapy
- Biomarker and companion diagnostic development
- Novel Antibodies

Day 2 Stream 1 – Discovery, Screening, Assays and Modelling in Immuno-Oncology

- Preclinical models including humanised mouse models
- Preclinical efficacy and assay development
- Approaches to preclinical combination therapy design
- Reducing toxicity challenges in immuno-oncology therapeutics
- Alternative screening strategies
- T-Cell engagement and immune monitoring
- Next generation cell lines and 3-D models of cancer
- Gene editing and genetic screens in in vivo and in vitro models
- Establishing partnerships and collaborations

Day 2 Stream 2 – Immuno-Oncology: Therapeutics Approaches, Clinical Research and Clinical Trials

- Approaches to clinical trial design & development
- Key safety challenges in cancer immunotherapy clinical trials
- Strategies for effective trial management
- Clinical data & case studies
  - Biomarker Strategy
  - Therapeutic cancer vaccines
  - Oncolytic viruses
  - T Cell Engagers
  - Bispecific Antibodies
- Clinical diagnostics & the potential of NGS in immuno-oncology clinical trials
- Predicting toxicity of immunotherapies
- Targeting patient specific neoantigens
- PD-L1 expression on cancer cells

Benefits to Attending

✓ **Network with key innovators in cancer immunotherapy.** Attendees will include VPs, Directors, and Heads of Department for Immuno-oncology, Clinical Trials, and Oncology Research from leading pharmaceutical and academic organisations in the field.

✓ **Discover collaborative solutions** for target discovery and engineering, immunotherapy development and clinical trial management. Find out how peers are advancing their research and overcoming challenges to the development of novel cancer therapeutics.

✓ **Discuss the latest innovations in cancer immunotherapy development strategies.** With preclinical and clinical case studies, delegates will have the chance to hear about the most exciting opportunities in molecular oncology research, as well as the latest progress in the study of B cells and CAR T pathways.

✓ **Unparalleled networking opportunities.** This two-day conference offers ample networking opportunities creating an interactive platform for high-level scientific and business discussions. Participate in formal or informal discussions during our networking breaks and pre-organised 1-2-1 meetings.

✓ **A high quality programme devised with the help of our esteemed advisory board.** Presentations will cover issues ranging from the discovery of novel immuno-oncology based treatments and clinical case studies to market opportunities and approach

2017 Speakers Include…

Philip Arlen
Precision Biologics, Inc

Jacqueline Doody
F-star Biotechnology

Ravi Madan
National Institutes of Health

Complimentary Live Webinars

- *'Immunotherapy of Bladder Cancer*. Hosted by Winald Gerritsen, Radboud University Medical Centre Nijmegen | Thursday 16th March 2017. Register today

Meet Senior Decision Makers

300 Professors, Directors & Consultants from leading pharmaceutical companies and academic institutions. Delegate job titles include:

Immuno-oncology	Cancer Vaccines	Clinical Oncology
Target Discovery	Strategic Partnering	Clinical Trial Management
Oncology Biomarkers	Agonist Antibodies	Immunotherapy

Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Clinical Development	Custom Antibodies	Cell Engineering
Strategic Partnerships	Clinical Management	T-Cell Engineering
Cell-based Assays	Diagnostics Development	Mouse Models
Antibody Engineering	Preclinical Discovery	In Vitro Screening

For booking details & registration fees please refer to the last page or visit:
www.immunooncology-congress.com/marketing

Confirmed Speakers

- Philip Arlen, President and Chief Executive Officer, Precision Biologics, Inc.
- Daniel Passeri, President & CEO, Cue Biopharma
- Russell LaMontagne, President and CEO, Boston Immune Technologies and Therapeutics
- Torsten Mummenbrauer, Senior Vice President Business Development, Hookipa Biotech
- Daniel Williams, Vice President Pipeline Operations , Adaptimmune
- Alan Graham Pockley, Professor of Immunobiology, Nottingham Trent University and CEO, multimmune GmbH
- Ulf Grawunder, Chief Executive Officer, NBE Therapeutics
- Karen LaRochelle, Chief Business Officer, PsiOxus Therapeutics
- Jonathan Zalevsky, Senior Vice President, Biology & Preclinical Development, Nektar Therapeutics
  Timothy Herpin, Vice President, Head of Transactions, Business Development, Astra Zeneca
- Jacqueline Doody, Vice President, F-star Biotechnology Ltd.
- Christopher Heery, Chief Medical Officer, Bavarian Nordic
- Christophe Quéva, Chief Scientific Officer Expertise in Oncology and Immunology, iTeos Therapeutics
- James Legg, Vice President, Research and Development, Crescendo Biologics
- Pieter Fokko van Loo, Director Translational Research, Merus N.V.
- Markus Mohrs, Director, Immuno-Oncology, Regeneron Pharmaceuticals
- Chan Whiting, Director of Immune Monitoring and Biomarker Development, Aduro Biotech
- Peter Dudek, Principal, Wellington Partners Life Science Venture Capital
- Cedrik Britten, Vice President, Head of Oncology Cell Therapy DPU, Oncology R&D, GlaxoSmithKline
- Sara Colombetti, Head of Oncology Discovery Pharmacology Department, Roche Innovation Center Zürich
- Guillaume Vignon, Global Head of Immuno-Oncology Licensing & Business Development, Merck KGaA
- David Krige, Head of Biomarkers, Immunocore Ltd.
- Geert. C. Mudde, Founder and CSO, OncoQR ML GmbH
- Nicolas Poirier, Chief Scientific Officer, OSE Immunotherapeutics
- Manuela Dürr, Project Leader of PRS-343, Pieris Pharmaceuticals
- Alfonso Quintas, Global Clinical Leader, Oncology, Novartis Institute for Biomedical Research
- Saso Cemerski, Principal Scientist, MSD
- Brian Haines, Principal Scientist *in Vivo* Pharmacology, MSD
- Matthew Albert, Principal Scientist, Cancer Immunology, Genentech
- Elena Brin, Research Fellow, Polaris Pharmaceuticals
- Peter Morley, Scientific Leader and GSK Associate Fellow, Biopharm Molecular Discovery, GlaxoSmithKline
- Ahmadur Rahman, Medical Lead, Immuno-Oncology, AstraZeneca
- David Dow, Early Program Leader, Cell and Gene Therapy, GlaxoSmithKline
- Luca Melchiori, Group Leader, T Cell Correlate Research, Adaptimmune
- Mike Giffin, Senior Scientist, Amgen
- Sandra Lazzaro, Immunotherapy Scientist, CureVac AG
- Pushpa Jayaraman, Investigator III, Novartis Institutes for BioMedical Research
- Christian Schmees, Head of Tumor Biology, NMI Reutlingen
- Ravi Madan, Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health
- Lenny Shultz, Professor, The Jackson Laboratory
- Paul Sondel, Reed and Carolee Walker Professor of Pediatrics, Human Oncology, and Genetics, University of Wisconsin
- Holger Lode, Professor and Chair of Pediatrics, University Medicine Greifswald
- Hardev Pandha, Professor of Medical Oncology, University of Surrey
- Winald Gerritsen, Professor of Tumour Immunotherapy, Radboud University Medical Centre Nijmegen
- Sophia Karagiannis, Reader in Translational Cancer Immunology, King's College London
- Ahuva Nissim, Reader Antibody and Therapeutics, Queen Mary University of London
- Jeanette Leusen, Head Immunotherapy Group of the Laboratory for Translational Immunology, University Medical Center Utrecht

2017 Sponsors Include:

2nd Annual Advances in Immuno-Oncology Congress
Day One – 15th May 2017

07.30 – 08.20	**Registration: Shannon Foyer**	
	Conference Room 1: Liffey Suite (1st Floor)	
08.20 – 08.25	**Oxford Global's Welcome Address**	
08.25 – 08.30	**Chairperson's Opening Address: Sofie Pattijn, Chief Technology Officer, ImmunXperts**	
08.30 – 09.00	**Engineered-Immune Cells As Treatments For Cancer Patients – The Past, Presence And Future** • Potential of engineered-cells to become broadly applied medicines • Key inhibitors of broad success • Enabling Technologies to maximize efficacy in solid cancer and to reach maximum access for patient • Need for Tue Innovation **Cedrik Britten, Vice President, Head of Oncology Cell Therapy DPU, Oncology R&D, GlaxoSmithKline**	
	Conference Room 1: Liffey Suite (1st Floor)	**Conference Room 2: Shannon 3**
	Discovery of Immuno-Oncology Therapies	**Pre-clinical Immuno-Oncology**
	Stream Chair: Sofie Pattijn, Chief Technology Officer, ImmunXperts	**Stream Chair: Sunita Mistry, Business Development Manager, Histologix**
09.00 – 09.30	**Targeting Immune Checkpoints With Humabody VH Domain Antibody Fragments** • Humabodies are the smallest antibody fragments • Humabody VH domain fragments have a number of advantages over whole Ig antibodies mAbs including very small size, robustness, expression yield and potential for multivalent engineering • Application of Humabody technology to Immune checkpoint blockade will be discussed **James Legg, Vice President, R&D, Crescendo Biologics**	**Novel Antibodies Against Immunogenic Neoantigens** • Use of a novel platform using immunogenic human tumor antigen for antibody development • Identification of Unique tumor specific monoclonal antibodies with anti-tumor activity and target antigens • Pre-clinical and clinical data in patients and future development plans **Philip Arlen, President and CEO, Precision Biologics, Inc.**

	Conference Room 1: Liffey Suite (1st Floor)	Conference Room 2: Shannon 3
09.30 – 10.00	**Modelling Aspects Of The Tumour Microenvironment In Order To Guide Development Of Novel Immune Modulating Cancer Therapies** • As the range of therapeutic targets grows, there is a clear need for bespoke assay systems that model different aspects of the tumour microenvironment (TME) • In vitro human cell biology assays can be supplemented with in vivo PD and efficacy models, where anti-tumour immunity can be assessed • As projects move into the clinic, careful validation of efficacy/PD and immunotoxicology biomarkers plays a critical role in adding value **Neil Williams, Founder and Chief Scientific Officer, KWS BioTest** KWSBioTest	**Interpreting Tissue-Based Immuno-Oncology Biomarkers Using Robust Image Analysis Solutions** • Understanding the tumour immune microenvironment in tissues from preclinical/clinical studies provides critical information for the drug discovery process on mode of action, efficacy and patient selection • Validation of immunohistochemistry immuno-oncology biomarker assays and application of next generation image analysis tools delivers valuable immunological insight into tumour immune processes • Robust approaches to the quantification, localisation and spatial relationships of immuno-oncology biomarkers in tumour tissues will be discussed **Marie Cumberbatch, Consultant to Histologix, Director, Immune Insight Limited** HistologiX IHC and Contract Histology
10.00 – 11.20	**Exhibition Room: Shannon 1&2** **Coffee & Refreshments, One to One Meetings x4, Poster Presentation Sessions**	
	Conference Room 1: Liffey Suite (1st Floor)	**Conference Room 2: Shannon 3**
11.20 – 11.50	**Combining Radiation Therapy, Intratumoral Immunocytokine And Checkpoint Blockade To Activate An In Situ Cancer Vaccine** • Tumor reactive antibody can be used to induce antibody-dependent cell mediated cytotoxicity via cells of the innate immune system • When an immune-activating cytokine is added, ADCC is enhanced and an adaptive response can be induced • Addition of immunomodulatory radiation therapy causes potentiation of innate and adaptive responses, enabling a tumor-specific memory T cell response • Activity can spread to distant sites (an abscopal effect) when checkpoint blockade is used and Tregs are inhibited **Paul Sondel, Reed and Carolee Walker Professor of Pediatrics, Human Oncology, and Genetics, University of Wisconsin**	**Humanized Mice In Cancer Research** • Humanized mice provide a bridge to preclinical studies on tumor cell biology and therapeutic response • Current humanized mouse models have a number of limitations that are being overcome in next generation models **Lenny Shultz, Professor, The Jackson Laboratory**
11.50 – 12.20	**Selective Anti-SIRPa: Next Generation Checkpoint Inhibitor Targeting Pro-Tumors And Suppressors Myeloid Cells** • Novel therapeutic strategies targeting accumulation of pro-tumoral and suppressive myeloid cells • Deciphering the SIRPa/CD47 pathways to generate selective checkpoint inhibitor • Preclinical data on selective anti-SIRPa mAb **Nicolas Poirier, Chief Scientific Officer, OSE Immunotherapeutics**	**Strategic Approaches To Address Tumors That Are Resistant To Immune Checkpoint Blockade** • The clinical success of immune checkpoint therapies such as CTLA-4 and PD-1 has revolutionized the treatment of many types of cancer • However, not all patients or cancer types respond to these therapies • Strategies will be discussed on how to engage both the innate and adaptive arms of the immune response, with the goal to enhance both the breadth and depth of response to checkpoint blockade **Brian Haines, Principal Scientist, *In Vivo* Pharmacology, MSD**

	Conference Room 1: Liffey Suite (1st Floor)	Conference Room 2: Shannon 3
12.20 – 12.50	**The Use Of In Vitro Assays To Accelerate Cancer Drug Development** • Application of a series of immune assays to screen the functionality of drug candidates • Product specific assay development • Common hurdles faces in assay development • Development of potency assays for cell therapy products **Sofie Pattijn, Chief Technology Officer, ImmunXperts**	**The Role Of Biomarkers, Companion And Complementary Diagnostics In Immuno-Oncology** • Review of tissue, cell and genomic based biomarkers relevant for immuno-oncology drug development • Overview of companion and complementary diagnostics in immuno-oncology **Steven Anderson, Senior Vice President, Laboratory Corporation of America, Chief Scientific Officer, Covance**
12.50 – 13.50	**Exhibition Room: Shannon 1&2** **Lunch**	
	Stream Chair: Neil Williams, Founder and Chief Scientific Officer, KWS BioTest	**Stream Chair: Marie Cumberbatch, Consultant to Histologix, Director, Immune Insight Limited**
13.50 – 14.20	**The Theranostic Potential Of Membrane Hsp70 In Oncology And The Development Of Natural Killer (NK) Cell-Based Cancer Therapeutics** In addition to being an intracellular molecule, heat shock protein 70 (Hsp70) is released from cancer cells, and it is widely and selectively expressed on the plasma membranes of the majority of tumour entities (~60 to 80%). Furthermore, chemo(radio)therapy can enhance the expression of the unique and selectively expressed membrane form of Hsp70. This presentation will provide a comprehensive insight into the theranostic potential of Hsp70 in oncology, by highlighting the therapeutic, targeting and imaging platforms that have been developed around this concept and how the technology might be able to enhance and improve current approaches for tumour targeting and imaging in a range of cancer settings. **Alan Graham Pockley, Professor of Immunobiology, Nottingham Trent University and CEO, multimmune GmbH**	**A Novel Adenosine A2A Receptor Antagonist Optimized For High Potency In Adenosine-rich Tumor Microenvironment Boosts Anti-tumor Immunity** High levels of extracellular adenosine in the tumor microenvironment are known to promote tumor immune suppression, tumor growth and metastasis. We defined the receptors required for mediating the effect of adenosine on immune cells within the tumor microenvionment and report the characterization of a novel Immuno-Oncology-dedicated adenosine receptor antagonist that functions in the high adenosine concentration found in tumors **Christophe Quéva, Chief Scientific Officer, iTeos Therapeutics**
14.20 – 14.50	**Developing Immunotherapy-based Combination Treatment Strategies** • Combinations with anti-androgen therapies in prostate cancer • Chemotherapy combinations • Radiation combinations **Ravi Madan, Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health**	**NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15** • IL-15 has well-recognized potential as an immunotherapeutic agent, but has suboptimal drug-like properties • NKTR-255 achieves sustained IL-15 signal and delivers a strong activation, proliferation, and survival signals to multiple immune cell types • NKTR-255 grows NK cells, modulates NK cell development and function **Jonathan Zalevsky, Senior Vice President, Biology & Preclinical Development, Nektar Therapeutics**

	Conference Room 1: Liffey Suite (1st Floor)	Conference Room 2: Shannon 3
14.50 – 15.20	**BioMAP Systems Capture Complexity Of Human Tumor Microenvironment To Support Development Of Immune Oncology Agents And Combinations** In general, current in vitro immune cell assays, as well as animal-xenograft models fail to recapitulate the complexity of the human tumor microenvironment (TME) containing tissue, immune and tumor cells. Additionally, most current methods are biased towards specific targets and target pathways. Moreover, these approaches poorly predict clinical responses and do not capture the broader impact on patient physiology outside the TME. We will present how the BioMAP disease models can help inform on agent with respect to: • Impact on efficacy related biomarkers in the BioMAP Oncology Systems modeling the complexity of the human TME • Effects of translation biomarkers related to safety and efficacy in the BioMAP Diversity PLUS modeling patient biology outside the TME • Novel approaches for testing monotherapies and combinations to validate and guide therapeutic strategies **Alison O'Mahony, Vice President, R&D Research Biology, DiscoverX**	**High Definition Multiplexing for Biomarker Discovery** • Biomarker discovery in immuno-oncology requires the analysis of multiple protein markers (n>4) with their spatial relationships at an amenable throughput • The scrutiny of the tumor micro-environment demands whole-slide multiplexed images featuring immune and tumor cells • Ultivue's InSituPlex platform fulfills this need with the data reproducibility relevant to CDx **Louis Levy, Director, Corporate and Business Development, Ultivue**
15.20 – 16.20	**Exhibition Room: Shannon 1&2** **Afternoon Refreshments, One to One Meetings x 3, Poster Presentation Sessions**	
16.20 – 16.50	**TheraT – Provoking A Sea Change In Immunotherapy** • Introduction of Hookipa'S TheraT platform offering unprecedented T cell responses for Cancer Immunotherapy • Development from homologous to heterologous Prime/Boost to optimize the therapeutic potency **Torsten Mummenbrauer, Senior Vice President Business Development, Hookipa Biotech**	**Highly Potent And Immune-Stimulatory Adcs With A Novel Anthracycline Toxin** • New data for novel ADCs with highly potent novel toxin in different tumor models • Update on immuno-oncology functionality of NBE-Therapeutics ADCs • Outlook internal NBE-Therapeutics' ADC development programs **Ulf Grawunder, Chief Executive Officer, NBE Therapeutics**
16.50 – 17.20	**Immune Response Induced By Anti-GD2 Antibody ch14.18/CHO In Neuroblastoma Patients Depends On Killer-Cell Ig-Like Receptor- And Fcγ-Receptor-Genotypes** • Clinical activity and efficacy of ch14.18/CHO against neuroblastoma • Impact of KIR-haplotypes and FCGR-polymorphisms on immune response and outcome • Potential to develop biomarker **Holger Lode, Professor and Chair of Pediatrics, University Medicine Greifswald**	**Developing Relevant Preclinical Models For Immunotherapy Pipeline Advancement** • Cancer immunotherapy: what's missing in most common preclinical tumour models for drug development • Moving towards "high bar" preclinical tumour models - immuno-competent and humanized models • In vivo profiling of cancer immuno-therapies in clinically relevant preclinical tumor models **Sara Colombetti, Head of Oncology Discovery Pharmacology Department, Roche Innovation Center Zürich**
17.20 – 17.50	**IgA As Novel Isotype To Treat Cancer** • IgA employs different effector mechanisms compared to IgG • IgA both for solid and hematological tumors in pre-clinical models • Half-life enhancement by glycoengineering and FcRn targeting **Jeanette Leusen, Head Immunotherapy Group of the Laboratory for Translational Immunology, University Medical Center Utrecht**	**Structural Guided Scaffold Libraries As A Source Of Bio-Therapeutic** • Build a structural guided library based on a ligand structure • Identify novel antibodies and peptide candidate for targeting treatment **Ahuva Nissim, Reader in Antibody and Therapeutics, Queen Mary University of London**

	Conference Room 1: Liffey Suite (1st Floor)	Conference Room 2: Shannon 3
17.50 – 18.20	**Dissecting Human B Cell And Antibody Immunity In Solid Tumours To Inform Oncology** • B cells and the antibodies they produce in solid tumours and the roles they play in disease course remains a largely unexplored area of immmunooncology • This talk will discuss the presence of an active B cell immune surveillance in tumours and the contribution of mature memory B cells with distinct immunoglobulin isotype-biased profiles • Our studies suggest that alternatively-activated humoral immune surveillance forms part of a defective anti-tumoural immune response to solid tumours such as melanoma • Humoral immunosignatures may also help guide patient stratification and inform the design of more effective immunotherapies **Sophia Karagiannis, Reader in Translational Cancer Immunology, King's College London**	**In vitro Characterization And In Vivo Anti-Tumor Efficacy Of A Novel STING Agonist, MK-1454** • Several innate immune, danger-sensing pathways have emerged as promising targets for enhancing cancer immunotherapy • STING agonists have demonstrated significant anti-tumor efficacy in syngeneic mouse tumor models and set the stage for STING agonists to be evaluated preclinically and advanced to the clinic • MK-1454 is a novel STING agonist that potently binds to both human and mouse STING and induces significant efficacy in vitro • In multiple mouse syngeneic tumor models, MK-1454 induced strong anti-tumor responses, inducing full tumor eradication upon intratumoral dosing, either as a single agent or in combination with PD-1 blockade **Saso Cemerski, Principal Scientist, MSD**
	Conference Room 1: Liffey Suite (1st Floor)	
18.20 – 18.50	**Round Table Discussions** **Moderator 1: Hardev Pandha, Professor of Medical Oncology, University of Surrey** **How Can We Optimise Patient And Disease Selection For The Use Of Checkpoint Inhibitors** **Moderator 2: Chan Whiting, Director of Immune Monitoring and Biomarker Development, Aduro Biotech** **Biomarker And Companion Diagnostic Development In Immuno-Oncology** **Moderator 3: Ahmadur Rahman, Medical Lead, Immuno-Oncology, AstraZeneca** **Developing Immunotherapy Combination Treatment Strategies** **Moderator 4: Geert. C. Mudde, Founder and CSO, OncoQR ML GmbH** **What Comes Next When The Checkpoint Inhibitor Hype Is Over?** **Moderator 5: Peter Morley, Scientific Leader and GSK Associate Fellow, Biopharm Molecular Discovery, GlaxoSmithKline** **Next Generation Antibodies In Immuno-Oncology** **Moderator 6: David Dow, Early Program Leader, Cell and Gene Therapy, GlaxoSmithKline** **The Future Of Cell Therapies In Immuno-Oncology**	
18.50	**Exhibition Room: Shannon 1&2** **Networking Drinks & End of Day One**	

	Conference Room 1: Liffey Suite (1st Floor)	Conference Room 2: Shannon 3
	Discovery, Screening, Assays and Modelling in Immuno-Oncology	**Immuno-Oncology: Therapeutic Approaches, Clinical Research and Clinical Trials**
	Stream Chair: Alison O'Mahony, Vice President, R&D Research Biology, DiscoverX	**Stream Chair: Dominic Eisinger, Vice President of Sales and Marketing, Myriad RBM**
08.30 – 09.00	**Stream Keynote Address:** **The Development Of Adoptive T Cell Therapies And Our Use Of Them To Treat Solid Tumours** • Adaptimmune's journey from small biotech to a clinical stage company • Development of TCR based T cell therapy pipeline • Clinical studies and current clinical result in solid tumours • Challenges to faced using T cell therapies • Forward thinking on development of Adaptimmune's therapeutics from targets to infrastructure **Daniel Williams, Vice President Pipeline Operations, Adaptimmune**	**Stream Keynote Address:** **Oncolytic Viruses As Single Agent Or Combination Immunotherapeutics** • Oncolytic viruses in practice- T-VEC • Rationale for various viruses as immunotherapies • Clincial trial data emerging • Combination with checkpoint inhibitors **Hardev Pandha, Professor of Medical Oncology, University of Surrey**
09.00 – 09.30	**Co-cultures Of Primary 3D Tumor Spheroids And Immune Cells For Preclinical Efficacy Testing Of Cancer Immuno And Combination Therapy** • Cellular models closely resembling patient tumors and their interactions with different aspects of the antitumor immune response are highly needed for predicting the efficacy of novel approaches in cancer immunotherapy alone and in combination with other treatments • Presentation of data from our co-culture model of primary 3D tumor spheroids with T and NK cells allowing for analysis of immune cell infiltration as well as cytotoxicity in response to antigen stimulation and/or compound treatment **Christian Schmees, Head of Tumor Biology, NMI Reutlingen**	**Biomarker Strategy To Inform Clinical Development Of ImmTACTM Molecules (Immune Mobilising TCRs Against Cancer)** A comprehensive biomarker strategy has been developed to compliment clinical studies with IMCgp100, an ImmTAC that targets malignant melanoma. This biomarker strategy is vital for evaluating ongoing trials as well as informing the clinical development of other ImmTAC molecules, either as single agents or in combination with checkpoint inhibitors. **David Krige, Head of Biomarkers, Immunocore Ltd**
09.30 – 10.00	**Innovative Solutions for Immuno-Oncology Drug Discovery** • Bespoke immunoassays with seamless project management for target validation, mode-of-action studies and combination immunotherapy design • *In vitro* and *in vivo* tumour-killing and immune response profiling. • Advanced multiplex histology for visualisation and co-localisation of targets **Stephen Anderton, Chief Scientific Officer, Aquila Biomedical Ltd** Aquila BioMedical	**Solution Provider Presentation** **Jim White, Technical Support Manager, NanoString** nanoString TECHNOLOGIES
10.00 – 11.20	**Exhibition Room: Shannon 1&2** **Morning Coffee & Refreshments, One to One Meetings x2 & Poster Presentations**	
11.20 – 11.50	**Tumor Associated Myeloid Cells Can Be Rendered Dysfunctional By The Tumor Microenvironment Through Expression Of TIM-3: Implications For TIM-3 Blockade In Cancer** • TIM-3, a T cell exhaustion marker, is more dominant on myeloid cells than on T cells in murine syngeneic tumor models and in renal cell carcinoma (RCC) treatment-naive patients. • We present data that TIM-3+ myeloid cells are dysfunctional, and that TIM-3 blockade rescues myeloid pro-inflammatory function • The pathophysiological role of the TIM-3 pathway in innate immunity might have important consequences on T cell function and TIM-3 blockade in cancer **Pushpa Jayaraman, Investigator III, Novartis Institutes for BioMedical Research**	**Immune Responses, *On Cue*: Targeted Immunotherapies to Modulate Activity of Disease Relevant T cells** • Description of Cue Biopharma's approach to developing first in class targeted immunotherapies for oncology and autoimmune diseases • Cue-101 design and pre-clinical supporting data • Overview of Cue Biopharma pipeline and autoimmune programs **Ronald D. Seidel, Executive Vice President, Head of Research and Development, Cue BioPharma**

<table>
<tr><td></td><td colspan="2">Conference Room 1: Liffey Suite (1st Floor)</td></tr>
<tr><td>11.50 – 12.20</td><td colspan="2">What Can Secreted Proteins Of The Immune System Tell Us About Patient Responses To Immuno-Oncology Treatments?
• Pharmacodynamic and prognostic blood-based proteins for immune-oncology clinical trials
• Immuno-oncology applications for TruCulture, a blood collection and culture tube for standardized immunophenotyping
• Quantifying cytokines at ultra-sensitive (fg/ml) levels for checkpoint blockade therapy

Dominic Eisinger, Vice President of Sales and Marketing, Myriad RBM

MYRIAD RBM</td></tr>
<tr><td>12.20 – 12.50</td><td colspan="2">Innovative Approaches To Immuno-Oncology Focusing On Spatial Analysis Of Multiplexed Immune Cell Markers Across The Tumour Boundary Utilising Whole Slide Imaging And Novel Image Analysis Techniques
• Digitisation: Discrete immune cell populations can revealed within high resolution images following automated segmentation of tumour regions
• Spatial arrangement of Immune markers: Visualising the proximity relationship between immune cells + tumour mass to increase prognostic value
• Efficacy: Rapid measurement of tumour microenvironment modulators
• Drug development: Facilitating rapid screening of novel anti-cancer compounds with Tissue Micro Array analysis

Sean Griffiths, Sales Application Scientist EMEA, Indica Labs

indica labs
informed pathology</td></tr>
<tr><td>12.50 – 13.50</td><td colspan="2">Exhibition Room: Shannon 1&2
Lunch</td></tr>
<tr><td></td><td>Conference Room 1: Liffey Suite (1st Floor)</td><td>Conference Room 2: Shannon 3</td></tr>
<tr><td></td><td>Stream Chair Invitation: Kate Lillard, Chief Scientific Officer, Indica Labs</td><td>Stream Chair: Dominic Eisinger, Vice President of Sales and Marketing, Myriad RBM</td></tr>
<tr><td>13.50 – 14.20</td><td>Genetically Engineered Mouse Models To Test Human Cancer Immunotherapies
• In vivo tumor models are critical to test the anti-tumor activity and side-effect profile of novel immunotherapeutics
• However, antibody-based therapies often do not cross react with the corresponding murine target, making such tests difficult * We have exploited genetic engineering of mice to develop different types of mouse tumor models with relevant immune cell targets
• We have used these models to develop both checkpoint inhibiting antibodies and T cell engaging bispecific antibodies

Markus Mohrs, Director, Immuno-Oncology Regeneron Pharmaceuticals</td><td>An Anti-murine LAG-3/PD-L1 Bispecific Antibody Which Modulates T Cell Activity and Inhibits Tumour Growth
• Bispecific antibody format that allows a “plug and play” modular strategy
• Anti-mouse LAG-3/PD-L1 bispecific antibody co-engages both antigens at nanomolar affinities with potent T cell activation
• Enhancement of in vivo activity in a bispecific format over combination therapy in a murine system

Jacqueline Doody, Vice President, F-star Biotechnology Ltd.</td></tr>
<tr><td>14.20 – 14.50</td><td>Panel Discussion:
Recent Deal Trends In Immuno-Oncology
• From the Biotech perspective: funding environment, partnerships and exits
• From the Pharma side: deal trends and emerging innovation
• Strategies and tactics for combination therapies

Moderator: Timothy Herpin, Vice President, Head of Transactions, Business Development, AstraZeneca

Panellists:
Peter Dudek, Principal, Wellington Partners Life Science Venture Capital

Guillaume Vignon, Global Head of Immuno-Oncology Licensing & Business Development, Merck KGaA

Karen LaRochelle, Chief Business Officer PsiOxus Therapeutics

Russell LaMontagne, President and CEO, Boston Immune Technologies and Therapeutics</td><td>MCLA-117, A Common Light Chain CLEC12AxCD3 Bispecific Antibody For AML
• MCLA-117, a novel full length human CLEC12AxCD3 bispecific IgG targeting the CLEC12A antigen on leukemic blasts and leukemic stem cells.
• MCLA-117 binds to cell types expressing CD3 and CLEC12A within the normal hematopoietic compartment, but not to early myeloid progenitors or hematopoietic stem cells.
• MCLA-117 redirects in primary AML samples autologous T cells to efficiently lyse CLEC12A^{+} AML blasts

Pieter Fokko van Loo, Director Translational Research, Merus N.V.</td></tr>
</table>

	Conference Room 1: Liffey Suite (1st Floor)	Conference Room 2: Shannon 3
14.50 – 15.20	**Costimulatory T-Cell Engagement By The 4-1BB/HER2 Bispecific PRS-343** • We provide a comprehensive update to the preclinical dataset around the 4-1BB/HER2 bispecific PRS-343 • Why immuno-stimulatory receptor targeting requires bispecifics for efficacy and safety in general • We show how the versatile Anticalin-based multispecifics platform allows selecting the optimal bispecific geometry for a desired biological effect **Manuela Dürr, Project Leader of PRS-343, Pieris Pharmaceuticals**	**The Rebirth Of Therapeutic Cancer Vaccines** • Previous vaccine "failures" due to ○ Poor technology ○ Poor clinical trial design ○ Better understanding of biology influences ○ Better trial design and patient selection ○ Need for combination strategies in many cases ○ Combination strategies ○ Standard therapy ○ Rationale selection for combination ○ Results in best use of immune stimulation and long term benefit ○ Checkpoint inhibition and other immunomodulatory agents ○ Objective response rates now possible end points ○ Biological correlative crucial to determine best strategy ○ Power of specific T cell induction ○ Antigen selection important ○ Antigen cascade effect now potentially measurable **Christopher Heery, Chief Medical Officer, Bavarian Nordic**
15.20 – 15.50	**Exhibition Room: Shannon 1&2** **Afternoon Coffee & Refreshments & Poster Presentation Sessions**	
15.50 – 16.20	**Which Patients With Urothelial Cancer To Treat With Immunotherapy?** • How to select patients for chemotherapy? • How to select patients for immunotherapy? **Winald Gerritsen, Professor of Tumour Immunotherapy, Radboud University Medical Centre Nijmegen**	**Therapeutic Cancer Vaccines With Intrinsic Adjuvant Function: Next Generation Checkpoint Control** • Active therapeutic vaccination against tumour associated targets • New mode of action with control over checkpoint (on/off) that normally prevent strong immune responses against autoantigens • Mobilization of the complete repertoire available for the immune system to attack tumours • No side effects • Human specific vaccines **Geert Mudde, Founder and Chief Scientific Officer, OncoQR ML GmbH**
16.20 – 16.50	**T Cell Immunotherapy For The Treatment Of Small Cell Lung Cancer** • Bi-specific T cell engager (BiTE®) molecules are a clinically validated modality and represent a promising therapeutic option to treat cancer • Delta-like Ligand 3 (DLL3) is a highly specific tumor associated antigen in Small cell lung cancer (SCLC), a highly aggressive tumor with a poor prognosis and limited therapeutic options • My talk will describe the generation and pre-clinical characterization of a half-life extended BiTE® targeting DLL3 with picomolar potency in vitro against SCLC cell lines and antibody-like pharmacokinetics (PK) in non-human primate PK studies **Mike Giffin, Senior Scientist, Amgen**	**Targeting Patient-Specific Neoantigens Using A Personalized, Live-Attenuated Double Deleted Listeria Monocytogenes (pLADD) Immunotherapy** • Personalized medicine treatment approach by targeting patient-specific neoantigens • Rationale and preclinical and clinical data supporting the development of pLADD immunotherapy • pLADD clinical development strategy and update will be discussed **Chan Whiting, Director of Immune Monitoring and Biomarker Development, Aduro Biotech**
	Conference Room 1: Liffey Suite (1st Floor)	
16.50 – 17.20	**Novel Approaches To Biomarkers Discovery In Adoptive Cell Therapy For Cancer** • Brief overview of Adaptimmune's technology • Helicopter view of possible approaches to Biomarker discovery in immunotherapy ○ Description of multicolour flow cytometry as tool for single cell analysis and description of different approaches to data analysis for multi-dimensional data ○ Description of single cell gene expression platform, including single cell RNA sequencing, as tool of discovery of biomarkers **Luca Melchiori, Group Leader, T Cell Correlate Research, Adaptimmune**	**RNAdjuvant®: A Novel, Highly Potent RNA-Based Immunomodulator With Strong Immunostimulatory Properties** • RNAdjuvant® improves the immunogenicity of different antigenic formats in preclinical models resulting in increased humoral and cellular immune responses • In clinical phase I study in healthy volunteers RNAdjuvant® was well tolerated and enhanced the immunogenicity of low dose licensed vaccine • Further Phase I clinical trials are in preparation to evaluate RNAdjuvant® in combination with peptide vaccines or as immunostimulator after intratumoral application **Sandra Lazzaro, Immunotherapy Scientist, CureVac AG**

	Conference Room 1: Liffey Suite (1st Floor)

17.20 - 17.50	**Immunomodulatory Properties Of PEGylated Arginine Deiminase**
	• Effect of PEGylated Arginine Deiminase treatment on
	  ○ PD-L1 expression on cancer and immune cells in vitro
	  ○ T cell subsets in healthy donor human peripheral blood mononuclear cells (PBMCs) under resting and activation conditions
	  ○ TILs in a poorly immunogenic syngeneic mouse melanoma model
	• Combination of PEGylated Arginine Deiminase and anti-PD-L1 mAb in a syngeneic mouse model
	
	Elena Brin, Research Fellow, Polaris Pharmaceuticals

17.50	**End of Conference**